OTCMKTS:PBIO

Pressure BioSciences - PBIO Stock Forecast, Price & News

$2.06

-0.08 (-3.75%)

(As of 01/30/2023 12:00 AM ET)

Add

Compare

Today's Range: $2.02
▼
$2.15
50-Day Range: $1.13
▼
$2.14
52-Week Range: $0.91
▼
$2.40

Volume: 33,872 shs
Average Volume: 30,707 shs
Market Capitalization: $25.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Pressure BioSciences (OTCMKTS:PBIO) Stock

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.

Receive PBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pressure BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PBIO Stock News Headlines

January 19, 2023 | finanznachrichten.de

Pressure BioSciences Inc.: Pressure BioSciences Nanoemulsions Platform Forging Game-Changing Future for Cannabis Industry

January 19, 2023 | finance.yahoo.com

Pressure BioSciences Nanoemulsions Platform Forging Game-Changing Future for Cannabis Industry

January 31, 2023 | Investing Trends (Ad)

Without Graphite, There Would Be ZERO EV Batteries!

Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.

December 22, 2022 | finance.yahoo.com

Pressure BioSciences Gives Guidance for Strong Q4 2022 Sales Followed by Rapid Revenue Growth from Multiple Large Industries in 2023

December 13, 2022 | finance.yahoo.com

Pressure BioSciences Announces First Commercial Production of Revolutionary UltraShear Nanoemulsion Product Shipped, Booked, and Paid

December 7, 2022 | finance.yahoo.com

Pressure BioSciences Partnership with QVC Skincare Leader Dr. Denese SkinScience Yields Unprecedented Effectiveness in Skin Tightening and Wrinkle Reduction

December 5, 2022 | finance.yahoo.com

Pressure BioSciences Securing and Fulfilling UltraShear Nanoemulsions Contracts, Discussed on "Stock Day Podcast"

November 22, 2022 | finance.yahoo.com

Pressure BioSciences, Inc. Reports Q3 2022 Financial Results and Offers Business Update on Ultra Shear Technology Nanoemulsions Commercialization Progress

January 31, 2023 | Investing Trends (Ad)

Elon Musk Claims Solar Will Soon Power the World

The world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.

October 26, 2022 | finance.yahoo.com

Pressure BioSciences and Leading Cosmeceuticals Innovator Dr. Denese SkinScience to Introduce Revolutionary UST Nanoemulsion Hair Regrowth Product in 2023

October 22, 2022 | forbes.com

Normal Blood Pressure Numbers According to Age

October 21, 2022 | finance.yahoo.com

Pressure BioSciences, Inc. (PBIO)

October 11, 2022 | finance.yahoo.com

Pressure BioSciences and Leading Cosmeceuticals Company Dr. Denese SkinScience Present Their Partnership Progress in FORCE Family Office October 13th Webinar

September 28, 2022 | finance.yahoo.com

Imminent Commercial Launch of Revolutionary UST Processing Method to be Focus of Pressure BioSciences Presentation at Emerging Growth Conference 40 on September 28, 2022

September 27, 2022 | finance.yahoo.com

Unique Advantages and Commercial Process Scalability of Pressure BioSciences Revolutionary UST Platform Illuminated at the Conference of Food Engineering 2022

September 13, 2022 | finance.yahoo.com

Pressure BioSciences to Expand on Pivotal Change in Business Strategy with Presentation at H. C. Wainwright Annual Global Investment Conference on September 13th

August 25, 2022 | msn.com

Novartis To Spinoff Sandoz Business To Create #1 European Generics Company

August 24, 2022 | finance.yahoo.com

Pressure BioSciences Secures Pivotal Cosmeceuticals Partnership for UST Platform With Dr. Denese SkinScience, 20-Year Leader With Over $0.5 Billion in QVC Sales

August 20, 2022 | marketwatch.com

InvestorNewsBreaks - Pressure BioSciences Inc. (PBIO) Enters Strategic Agreement with Canopy CBD Farms

August 19, 2022 | seekingalpha.com

Pressure Biosciences announces contract for October launch of hemp-derived CBD product

August 18, 2022 | finanznachrichten.de

Pressure BioSciences Inc.: Pressure BioSciences, Inc. to Discuss Second Quarter 2022 Financial Results and Provide Business Update

August 18, 2022 | finance.yahoo.com

Pressure BioSciences Announces Contract for October 2022 Launch of Breakthrough Hemp-Derived CBD Product, Estimating $2 Million Incremental 2023 Revenue

August 16, 2022 | finance.yahoo.com

Pressure BioSciences, Inc. to Discuss Second Quarter 2022 Financial Results and Provide Business Update

August 5, 2022 | finance.yahoo.com

Pressure BioSciences Doubles Growth Projections for UST Nanoemulsion Contracts Following Clear Confirmation of Unmet Needs in Exploding Cannabis Drinks Sector

July 21, 2022 | finance.yahoo.com

Pressure BioSciences Announces Second Contract for Toll Manufacturing of a CBD Nanoemulsion Product Using Its Proprietary Ultra Shear Technology Platform

July 6, 2022 | finance.yahoo.com

Pressure BioSciences to Expand on Upcoming Release of CBD Nanoemulsion Oral Spray at July 6th Emerging Growth Conference - Annual Revenue to PBI Expected to Exceed $1M

July 2, 2022 | morningstar.com

Pressure BioSciences to Participate in FORCE Family Office June 30th Webinar: Revolutionizing the Development of Plant-Based Food Products | Morningstar

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pressure BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PBIO Company Calendar

Last Earnings: 11/22/2022
Today: 1/31/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Analytical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:PBIO
CUSIP: N/A
CIK: 830656
Web: www.pressurebiosciences.com
Phone: 508-230-1828
Fax: 508-230-1829
Employees: 12
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,150,000.00
Net Margins: -1,078.50%
Pretax Margin: -1,078.43%
Return on Equity: N/A
Return on Assets: -541.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.06
Quick Ratio: 0.02

Sales & Book Value

Annual Sales: $2 million
Price / Sales: 12.88
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.63) per share
Price / Book: -0.78

Miscellaneous

Outstanding Shares: 12,540,000
Free Float: 10,708,000
Market Cap: $25.77 million
Optionable: Not Optionable
Beta: 0.59

Key Executives

Mr. Richard T. Schumacher (Age 73)
Founder, Pres, CEO, Treasurer, Interim CFO, Clerk & Director
Comp: $355.18k

Dr. Alexander V. Lazarev Ph.D. (Age 58)
Chief Science Officer
Comp: $202.34k

Dr. Edmund Y. Ting Ph.D. (Age 68)
Sc.D. Ph.D., Sr. VP of Engineering
Comp: $256.92k

John B. Hollister
Director of Sales & Marketing

Key Competitors

View All Competitors

PBIO Stock - Frequently Asked Questions

How have PBIO shares performed in 2023?: Pressure BioSciences' stock was trading at $1.30 at the start of the year. Since then, PBIO shares have increased by 58.1% and is now trading at $2.0550.
View the best growth stocks for 2023 here.
Are investors shorting Pressure BioSciences?: Pressure BioSciences saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 5,300 shares, a decrease of 18.5% from the December 31st total of 6,500 shares. Based on an average daily volume of 32,700 shares, the short-interest ratio is currently 0.2 days.
View Pressure BioSciences' Short Interest.
How were Pressure BioSciences' earnings last quarter?: Pressure BioSciences, Inc. (OTCMKTS:PBIO) issued its quarterly earnings data on Tuesday, November, 22nd. The company reported ($0.44) EPS for the quarter. The company had revenue of $0.14 million for the quarter.
What other stocks do shareholders of Pressure BioSciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pressure BioSciences investors own include Advanced Micro Devices (AMD), Allena Pharmaceuticals (ALNA), Ampio Pharmaceuticals (AMPE), Actinium Pharmaceuticals (ATNM), Anavex Life Sciences (AVXL), Aware (AWRE), Curaleaf (CURLF) and Walt Disney (DIS).

What is Pressure BioSciences' stock symbol?: Pressure BioSciences trades on the OTCMKTS under the ticker symbol "PBIO."
How do I buy shares of Pressure BioSciences?: Shares of PBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pressure BioSciences' stock price today?: One share of PBIO stock can currently be purchased for approximately $2.06.
How much money does Pressure BioSciences make?: Pressure BioSciences (OTCMKTS:PBIO) has a market capitalization of $25.77 million and generates $2 million in revenue each year. The company earns $-20,150,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.
How can I contact Pressure BioSciences?: Pressure BioSciences' mailing address is 14 NORFOLK AVENUE, SOUTH EASTON MA, 02375. The official website for the company is www.pressurebiosciences.com. The company can be reached via phone at 508-230-1828, via email at ir@pressurebiosciences.com, or via fax at 508-230-1829.

This page (OTCMKTS:PBIO) was last updated on 1/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial